

**North of Tyne, Gateshead and North Cumbria
Area Prescribing Committee**
www.northoftyneapc.nhs.uk
Tuesday 6th July 2021 12:30 pm
[Join Microsoft Teams Meeting](#)

AGENDA

1.	Apologies for absence Nicola Allen	
2.	Declarations of interest	
3.	Appeals against previous decision	
4.	Election of officers	
5.	Terms of reference – for review	Enc.1.
6.	Minutes from the meeting 13/4/21 Decision summary from 13/4/21	Enc.2. Enc.3.
7.	Matters arising not on the agenda	
8.	APC Action log <ul style="list-style-type: none"> • update 	Enc.4.
9.	Report from the Formulary sub-group <ul style="list-style-type: none"> • Draft minutes from meeting held on 10/6/21 	Enc.5.
10.	Report from the Medicines Guidelines and Use Group <ul style="list-style-type: none"> • Draft minutes from meeting held on 7/6/21 • Guidance/documents to approve: <ul style="list-style-type: none"> ○ Antiplatelet guidance - update ○ Prescribing intervals - update ○ Children`s ADHD shared care guidance - update ○ Melatonin shared care guidance for the management of Sleep/Wake Disorders in Children and Young People : update ○ Bariatric - management of patients, post-bariatric surgery, in primary care ○ Immunosuppression liver transplant 	Enc.6. Enc.7. Enc.8. Enc.9. Enc.10. Enc.11. Enc.12. t/f
11.	Opiate/pain management sub-group <ul style="list-style-type: none"> • Update from meeting held on 16/6/21 • Data 	Enc.13. Enc.14.
12.	ICS <ul style="list-style-type: none"> • IMD shared care update • Regional survey on LDMs – response submitted 	Enc.15.

13.	RMOCs <ul style="list-style-type: none"> • Shared care consultation notifications • Terms of reference consultation (link) 	Emails 10/5/21 & 7/6/21 Email 20/5/21
14.	<p>Northern (NHS) Treatment Advisory Group (NTAG). http://ntag.nhs.uk/</p> <p>The following recommendations were updated by NTAG at their meeting on the 8th June 2021 and are now available on the website:</p> <ul style="list-style-type: none"> • Perampanel (Fycompa®) for Partial-onset (focal) epilepsy – updated recommendation to include license extension in children under 12 years old. • Transanal Irrigation Systems (TAIs) for neurogenic bowel dysfunction, chronic constipation, and chronic faecal incontinence – updated to replace Peristeen with Peristeen Plus as Peristeen discontinued by manufacturer. • Infliximab Subcutaneous (Remsima®) – reviewed and no change to recommendation that this is an option during Covid-19 Pandemic. To be reviewed again in 6 months. • Dupilumab and Omalizumab for chronic rhinosinusitis with nasal polyps - updated to note that not recommended as NICE TA terminated. • Transcutaneous vagus nerve stimulation for treatment of cluster headache and migraine – updated to reflect change in funding arrangements. Now CCG commissioned and funded. <p>The following recommendations were archived as now superseded by NICE TA or NHSE guidance:</p> <ul style="list-style-type: none"> • Andexanet alfa (Ondexxya®) Factor Xa inhibitor antidote 	Enc.16. Enc.17. Enc.18. Enc.19. Enc.20.
15.	<p>NICE Technology Appraisals published since last meeting</p> <ul style="list-style-type: none"> • TA692 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Negative appraisal • TA693 Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer • TA694 Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia • TA695 Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma • TA696 Tafamidis for treating transthyretin amyloidosis with cardiomyopathy – negative appraisal • TA697 Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban • TA698 Ravulizumab for treating paroxysmal nocturnal haemoglobinuria • TA699 Ofatumumab for treating relapsing multiple sclerosis • TA700 Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) • TA701 Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) 	Enc.21.

	<ul style="list-style-type: none"> • TA702 Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) • TA703 Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) • TA704 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies • TA705 Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer • TA706 Ozanimod for treating relapsing–remitting multiple sclerosis – negative appraisal • TA707 Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer • TA708 Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis • TA709 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency • TA710 Ravulizumab for treating atypical haemolytic uraemic syndrome 	
16.	<p>NHS England</p> <ul style="list-style-type: none"> • Specialised Services circulars <ul style="list-style-type: none"> ○ SSC2247 NICE Technology Appraisal Final Appraisal Determination: Trastuzumab deruxtecan for treating HER2- positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies ○ SSC2248 NICE Technology Appraisal Final Appraisal Determination: atezolizumab monotherapy for untreated advanced non-small-cell lung cancer ○ SSC2250 ‘Specialised Commissioning Update’ ○ SSC2251 - Nivolumab for prev treated unresectable adv oesophageal cancer ○ SSC2252 - osimertinib adjuvant EGFR +ve NSCLC ○ SSC2253 - Pembro 1L MSI-H MMR colorectal cancer ○ SSC2259 Specialised Commissioning Update ○ SSC2262 NICE Technology Appraisal Final Appraisal Determination: enzalutamide for treating hormone-sensitive metastatic prostate cancer ○ SSC2263 NICE Technology Appraisal Final Appraisal Determination: nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency 	Enc.22.
17.	Chairman’s action	
18.	Any other business	
19.	<p>Date, time and venue of next meeting.</p> <ul style="list-style-type: none"> • Tuesday 19th October 12.30 pm <p>Cobalt conference centre, Level 2 Northumbria Healthcare NHS Foundation Trust</p>	

	<p>Northumbria House 7-8 Silver Fox Way Cobalt Business Park North Shields NE27 0QJ Tea/coffee will be available from 12:15 pm Dial in option: Join Microsoft Teams Meeting</p>	
--	---	--